Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 2/20 | 0.41 |
| ▸ | MC5R | P33032 | 2/20 | 0.41 |
| ▸ | MC1R | Q01726 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072408 | 0.87 | TSHR (0.53) | CFTRPIN1MEN1KMT2APDK1 | |
| SCHEMBL5071312 | 0.78 | HDAC1 (0.51) | HDAC1HDAC6CFTRCHRNB2CHRNA4 | |
| SCHEMBL5370774 | 0.77 | PDK1 (0.48) | CFTRPIN1MEN1KMT2APDK1 | |
| SCHEMBL5070018 | 0.76 | HDAC1 (0.49) | HDAC1HDAC6CFTRNR1D1CHRNB2 | |
| SCHEMBL5359598 | 0.76 | PIN1 (0.55) | PIN1MEN1KMT2ALTB4R2TSHR | |
| SCHEMBL5074340 | 0.75 | HDAC1 (0.53) | HDAC1HDAC6CFTRMEN1KMT2A | |
| SCHEMBL5366161 | 0.74 | CFTR (0.54) | HDAC1HDAC6CFTRNR1D1PDK1 | |
| SCHEMBL5361120 | 0.74 | MEN1 (0.58) | MEN1KMT2ALTB4R2C5AR1TSHR | |
| SCHEMBL5353976 | 0.72 | MEN1 (0.71) | CFTRCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL5358691 | 0.72 | MAPT (0.42) | PIN1MEN1KMT2ALTB4R2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487796-A4 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | claimed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | claimed |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | claimed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7148225-B2 | Substituted biaryl amides as C5A receptor modulators | NEUROGEN CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2006-08-10 | — | — | US | disclosed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | disclosed |
| US-6858637-B2 | Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide | NEUROGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | HDAC1 1197/4885HDAC6 2604/4885CFTR 2241/4885 |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | C5AR1, C5AR2, C3AR1 | HDAC1 1257/4885HDAC6 2578/4885CFTR 2330/4885 |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | HDAC1 1257/4885HDAC6 2578/4885CFTR 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.